MEGATOPE
LOE Approachingiodinated i-131 albumin
BLAINJECTIONINJECTABLE
Approved
Feb 1976
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
MEGATOPE (iodinated i-131 albumin) is clinical pharmacology following intravenous injection, iodinated i 131 albumin is distributed throughout the intravascular pool within 10 minutes; extravascular distribution takes place more slowly. Approved for plasma volumes. First approved in 1976.
Drug data last refreshed 18h ago · AI intelligence enriched 2mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MEGATOPE is an iodinated I-131 albumin radiopharmaceutical administered intravenously for plasma volume measurement. The drug distributes throughout intravascular and extravascular spaces over 2-4 days, with radioactivity eliminated primarily through urine. It functions as a diagnostic agent to quantify circulating blood volume in clinical settings.
LOE Approaching
Product approaching end-of-life with minimal linked job openings; teams are likely consolidating or transitioning to emerging diagnostic platforms.
Mechanism of Action
CLINICAL PHARMACOLOGY Following intravenous injection, iodinated I 131 albumin is distributed throughout the intravascular pool within 10 minutes; extravascular distribution takes place more slowly. Iodinated I 131 albumin also can be detected in the lymph and in certain body tissues within 10…
Indications (1)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.